Antibe Therapeutics (OTCMKTS:ATBPF) Shares Down 1.3%

Antibe Therapeutics Inc. (OTCMKTS:ATBPFGet Rating)’s share price was down 1.3% on Monday . The stock traded as low as $0.48 and last traded at $0.48. Approximately 7,000 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 11,502 shares. The stock had previously closed at $0.48.

The firm has a market capitalization of $24.93 million, a PE ratio of -1.14 and a beta of 0.29. The company has a fifty day moving average price of $0.55 and a two-hundred day moving average price of $0.56.

Antibe Therapeutics Company Profile (OTCMKTS:ATBPF)

Antibe Therapeutics Inc, a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.